Dr. Eric C. Mueller, M.D.
Rheumatology (Rheumatology Physician)
105 W 8th Ave, Suite 6080
Spokane, WA 99204
Who else practices at this address →
Spokane County includes primary care (67% of residents) and dental (43% of residents) and mental health (29% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Washington School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 580
Licensed in Washington since 2008, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Washington School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
WA license MD60014592 (first issued 2008; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tacoma General Allenmore Hospital Tacoma, WA
- Prov Sacred Hrt Med Ctr & Childs Hosp. Spokane, WA
- Kootenai Health Coeur D'alene, ID
- Pullman Regional Hospital Pullman, WA
- Coulee Medical Center Grand Coulee, WA
Medical groups
- Arthritis Northwest PLLC (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 580
- Services billed
- 89,823
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, infliximab, excludes biosimilar, 10 mg | 6,155 | 21 |
| Injection, denosumab, 1 mg | 1,560 | 17 |
| Established patient office or other outpatient visit, 30-39 minutes | 502 | 389 |
| Measurement c-reactive protein for detection of infection or inflammation | 488 | 300 |
| Red blood cell sedimentation rate, to detect inflammation, automated | 481 | 296 |
| Blood test, comprehensive group of blood chemicals | 462 | 279 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 440 | 270 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 353 | 53 |
| Insertion of needle into vein for collection of blood sample | 345 | 271 |
| Measurement of antibody for assessment of autoimmune disorder, any method | 238 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methotrexate (methotrexate sodium) Other prescribers in Spokane, WA | 480 |
| Hydroxychloroquine Sulfate Other prescribers in Spokane, WA | 385 |
| Prednisone Other prescribers in Spokane, WA | 310 |
| Meloxicam Other prescribers in Spokane, WA | 105 |
| Folic Acid Other prescribers in Spokane, WA | 87 |
| Tramadol Hcl Other prescribers in Spokane, WA | 87 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Spokane, WA | 83 |
| Gabapentin Other prescribers in Spokane, WA | 81 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Spokane, WA | 72 |
| Mycophenolate Mofetil Other prescribers in Spokane, WA | 70 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 93 payments worth $1,938 in total to this clinician.
| AbbVie Inc. | $577 |
|---|---|
| Amgen Inc. | $438 |
| AstraZeneca Pharmaceuticals LP | $227 |
| Lilly USA, LLC | $171 |
| UCB, Inc. | $161 |
| Novartis Pharmaceuticals Corporation | $94.85 |
| Genzyme Corporation | $68.19 |
| GlaxoSmithKline, LLC. | $62.67 |
| Food and Beverage | $1,938 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $1,778,086 in research payments for these studies, mostly to the institutions running them.
- A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants
Amgen Inc. - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
AbbVie Inc. · Active, not recruiting · NCT03671148 - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
UCB SA · Completed · NCT06624228 - A Study of Baricitinib in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT04086745 - Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
Sun Pharmaceutical Industries Inc. - M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
AbbVie Inc. - INSPIRE LTE study
Sun Pharmaceutical Industries Inc. - A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT03915964 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity
Amgen Inc. - A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.